Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30

Benzinga · 1d ago
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:VCYT) with a Overweight and lowers the price target from $54 to $30.